TW200815455A - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
TW200815455A
TW200815455A TW096130206A TW96130206A TW200815455A TW 200815455 A TW200815455 A TW 200815455A TW 096130206 A TW096130206 A TW 096130206A TW 96130206 A TW96130206 A TW 96130206A TW 200815455 A TW200815455 A TW 200815455A
Authority
TW
Taiwan
Prior art keywords
epothilone
doc
disease
representative
treating
Prior art date
Application number
TW096130206A
Other languages
English (en)
Chinese (zh)
Inventor
Ernst Kusters
Michael Mutz
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37685905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200815455(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200815455A publication Critical patent/TW200815455A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW096130206A 2006-08-16 2007-08-15 Organic compounds TW200815455A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119043 2006-08-16

Publications (1)

Publication Number Publication Date
TW200815455A true TW200815455A (en) 2008-04-01

Family

ID=37685905

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096130206A TW200815455A (en) 2006-08-16 2007-08-15 Organic compounds

Country Status (22)

Country Link
US (1) US8178566B2 (enExample)
EP (1) EP2064216A2 (enExample)
JP (1) JP2010500387A (enExample)
KR (1) KR20090038902A (enExample)
CN (1) CN101506217B (enExample)
AR (1) AR062375A1 (enExample)
AU (1) AU2007286454A1 (enExample)
BR (1) BRPI0715963A2 (enExample)
CA (1) CA2658475A1 (enExample)
CL (1) CL2007002362A1 (enExample)
IL (1) IL196558A0 (enExample)
MA (1) MA30656B1 (enExample)
MX (1) MX2009001635A (enExample)
MY (1) MY148355A (enExample)
NO (1) NO20091081L (enExample)
NZ (1) NZ574194A (enExample)
PE (1) PE20081317A1 (enExample)
RU (1) RU2009109352A (enExample)
TN (1) TN2009000044A1 (enExample)
TW (1) TW200815455A (enExample)
WO (1) WO2008019820A2 (enExample)
ZA (1) ZA200900227B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146638A1 (en) 2010-05-18 2011-11-24 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
CN103910742B (zh) * 2013-01-07 2016-07-13 浙江海正药业股份有限公司 一种制备埃博霉素b无定形粉末的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1052974B1 (en) 1998-02-05 2009-05-20 Novartis AG Pharmaceutical formulation containing epothilone
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds
BRPI0314133A8 (pt) * 2002-09-23 2017-09-19 Bristol Myers Squibb Co Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona

Also Published As

Publication number Publication date
CL2007002362A1 (es) 2008-08-08
AU2007286454A1 (en) 2008-02-21
MY148355A (en) 2013-03-29
CN101506217B (zh) 2012-09-05
WO2008019820A3 (en) 2008-04-17
IL196558A0 (en) 2009-11-18
TN2009000044A1 (en) 2010-08-19
US8178566B2 (en) 2012-05-15
WO2008019820A2 (en) 2008-02-21
NO20091081L (no) 2009-03-16
AR062375A1 (es) 2008-11-05
BRPI0715963A2 (pt) 2013-08-06
KR20090038902A (ko) 2009-04-21
JP2010500387A (ja) 2010-01-07
CN101506217A (zh) 2009-08-12
NZ574194A (en) 2011-12-22
PE20081317A1 (es) 2008-10-28
MA30656B1 (fr) 2009-08-03
CA2658475A1 (en) 2008-02-21
RU2009109352A (ru) 2010-09-27
US20100160393A1 (en) 2010-06-24
EP2064216A2 (en) 2009-06-03
ZA200900227B (en) 2009-12-30
MX2009001635A (es) 2009-02-23

Similar Documents

Publication Publication Date Title
TW457095B (en) Pharmaceutical formulations comprising epothilones and lyophilised compositions comprising epothilones
EP1797874B1 (en) Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation
FR2775187A1 (fr) Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
JP5952890B2 (ja) 膵臓癌を治療するための医薬製剤
EP3547999A1 (en) Calcium lactate compositions and methods of use
CN109745287A (zh) 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
EP2263668B1 (en) Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors
CN103788043B (zh) 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途
CN101423519A (zh) 粉防己碱有机酸盐及制备方法和应用
CN105997942B (zh) 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用
CA2900508C (en) Cabazitaxel composition
TW200815455A (en) Organic compounds
CA2627544A1 (en) Formulations of quinolinones for the treatment of cancer
Xie et al. MMAE-loaded PLGA nanomedicine with improved biosafety to achieve efficient antitumor treatment
JP7105465B2 (ja) キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法
RU2195937C1 (ru) Комбинированный противотуберкулезный препарат (ризобутол)
KR20250013306A (ko) 페오놀 및 아포시닌을 포함하는 액체 제형
CN113456643A (zh) 一种含普那布林的药物组合及其应用
TW201235038A (en) Sensitizer, kit and use for cancer therapy
WO2008061429A1 (fr) Procédé d'utilisation de triacontanol visant à préparer des médicaments destinés à traiter des cancers
JP2010500387A5 (enExample)
CN101559037A (zh) 用于静脉和脑内注射的两元溶液型制剂
Pedro Formulações à Base de Solventes Eutécticos Profundos para o Desenvolvimento de Sistemas de Administração de Fármacos
JP2833821B2 (ja) 抗癌剤
WO2023016495A1 (zh) 含有白果内酯和大麻二酚的药物组合物及其在医药上的应用